Costas, Inc. (OTC PINK: CSSI), also known as Standard Dental Labs Inc. (SDL), has maintained impressive gross profit margins of over 40% for the past four quarters.
The company’s profits are derived from the manufacturing of dental implants, dental prosthetics, and various other dental lab services and products. It is dedicated to expanding its business through internal growth and potential acquisitions of similar dental labs in the Orlando, Florida area. With sufficient capital available, the company plans to pursue ongoing acquisitions of dental labs.
The dental lab operations of SDL continue to progress steadily. While the manufacturing business continues, the company actively seeks capital to lay the foundation for acquiring additional labs in the Orlando, Florida area. Any future lab acquisitions, if realized, would enable management to execute the company’s business plan, including the consolidation of previously acquired labs such as Prime Dental Lab. As of now, there are no capital commitments in place.
Management believes that the most expedient route to company growth is through the acquisition-driven model, a strategy successfully employed in numerous other industries. The consolidation of large pharmaceutical companies ushered in a new era of growth through acquisitions in the early 1970s, and there are still significant market consolidations to be made. Standard Dental Labs Inc. (OTC: CSSI) is dedicated to consolidation within the US Dental Lab Industry. While consolidators have achieved remarkable success, it’s important to acknowledge the significant competition in this arena.
While the pharmaceutical industry regularly makes headlines for mega-mergers and acquisitions, many other industries conduct mergers more discreetly. Dental and medical clinics are particularly relevant to SDL. The rising M&A activity in these sectors offers valuable insights and a roadmap for Standard Dental Labs’ future progress.
Since March 2022, this quote exemplifies the extraordinary liquidity delivered to investors and dentists alike. Standard Dental Labs is effectively replicating this, but as of now, we have yet to identify any direct competition.
“In the last 60 days of 2021, invisible dental support organizations (IDSOs) monetized more than $4 billion in value for their doctor partners and investors. That was in addition to $1.4 billion in the first 30 days of 2021 for a single IDSO. In 2022, there will be tens of billions of dollars returned to doctors and investors as dozens more IDSOs and DSOs recapitalize or sell to larger investors. Some doctors and investors will achieve returns of three to 10 times or more on their equity in many of these transactions, some in less than three years.
Today, hundreds of IDSOs in all 50 states are eager to partner with dentists of every specialty. IDSOs purchase 51% to 90% of a practice at record values for cash up front. Doctors retain ownership and continue to lead their practices as owners—with the doctor’s brand, team, and strategy—for years or even decades. An IDSO partnership is not a short-term transition strategy, but rather a wealth-building partnership.”
– Dental Economics – March 2022
Costas, Inc. (CSSI), now doing business as Standard Dental Labs Inc., is a company engaged in discovering, acquiring, and developing dental labs throughout the United States. The company plans to acquire independent labs looking to exit the market or who may be interested in retirement. Acquiring labs will be the focus of our growth strategy. Labs will be consolidated into one regionally central lab, and continue to operate, adding revenue to the company’s income statement. All North American markets with populations over 1 million are targets. The company is headquartered in Orlando, Florida.
For more information, visit https://standarddentallabs.com.
This press release and the statements of representatives of Costas, Inc. (the “Company”) related thereto contain, or may contain, among other things, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are “forward-looking statements,” including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as “guidance,” “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “ultimately” or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
The company’s actual results (including, without limitation, Costas’ ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the company files with OTC Markets (Pink Sheets). All forward-looking statements attributable to the company or persons acting on its behalf are expressly qualified in their entirety by these factors. The company undertakes no duty to update these forward-looking statements except as required by law.